Skip to main content

28-01-2022 | Immunotherapy | Video

Recent developments in immunotherapy for patients with mUC (ESMO IO)

SpeakersMichiel Van der Heijden and Ignacio Durán Martínez

Michiel Van der Heijden and Ignacio Durán Martínez share their thoughts on the use of maintenance therapy after first-line chemotherapy for metastatic urothelial cancer and discuss new strategies in first line, such as single agent immunotherapy compared with chemotherapy and chemo-immuno combinations. They also comment on the upcoming results of the CheckMate 901 trial of nivolumab plus ipilimumab versus chemotherapy and highlight EV-302 study of enfortumab vedotin plus pembrolizumab compared with chemotherapy (21:23).

This independent programme is supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany